Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Atea reported cash and investments of $219.5 million at the end of Q2 2026, down from $301.8 million at year-end 2025, with a net loss of $0.41 per share for the quarter. The company provided an update on its Phase 3 C-BEYOND trial, where BEM/RZR achieved a 93.9% sustained virologic response rate, meeting the primary endpoint of non-inferiority compared to Epclusa. Atea plans to submit a New Drug Application to the FDA in the second quarter of 2027. Pipeline progress includes completion of enrollment in the C-FORWARD Phase 3 trial, with topline results expected in early Q1 2027, and the initiation of a Phase 1 trial for AT-587 for the treatment of Hepatitis E.

•2mo ago

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Atea Pharmaceuticals reported positive Phase 3 topline data from the C-BEYOND trial, where its BEM/RZR regimen achieved statistical non-inferiority to Gilead's Epclusa (SOF/VEL) in treating chronic hepatitis C. In the modified intent-to-treat population, BEM/RZR achieved a 93.9% cure rate (SVR24) versus 94.8% for the standard of care, with notably high efficacy maintained in both cirrhotic and non-cirrhotic patients. Crucially, the data supports an 8-week treatment duration for patients without cirrhosis—who comprise roughly 80-90% of the HCV population—potentially offering a shorter, more convenient regimen than the current 12-week standard. The company expects to report results from its second Phase 3 trial, C-FORWARD, in early 2027, which covers a broader range of genotypes outside North America.

•3mo ago

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Atea Pharmaceuticals initiated a first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus (HEV). The randomized, double-blind study is designed to evaluate the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers. Preclinical data presented at EASL 2026 demonstrated that AT-587 is 30- to 150-fold more potent in vitro against HEV than current off-label treatments sofosbuvir and ribavirin. There are currently no approved therapies for HEV, which poses a significant risk to immunocompromised patients. The trial includes single and multiple ascending dose components, with dose escalation decisions guided by ongoing safety and pharmacokinetic data reviews.

•3mo ago

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Atea Pharmaceuticals completed patient enrollment in its Phase 3 C-FORWARD trial evaluating the BEM/RZR regimen for hepatitis C, enrolling more than 880 patients across 17 countries. Topline results from C-FORWARD are expected around year-end 2026, while data from the North American C-BEYOND trial remains on track for mid-year 2026. The company positions the BEM/RZR regimen as a potentially best-in-class option with short treatment duration and low risk of drug-drug interactions.

•4mo ago

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Atea Pharmaceuticals presented Phase 1 data at EASL Congress 2026 showing its lead HCV regimen, BEM/RZR, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. The results support co-administration without dose adjustments, reinforcing the regimen's potential best-in-class profile as the company approaches topline Phase 3 results from the C-BEYOND and C-FORWARD trials. Atea also shared preclinical data for AT-587, a potential first-in-class antiviral for Hepatitis E Virus (HEV), demonstrating high potency and efficacy in gerbil models, with a first-in-human study planned for mid-2026.

•5mo ago